Efficacy and safety of movalis (meloxicam) injected into trigger points of 94 patients with vertebrogenic lumbago-ischialgia syndrome have been assessed. Patients have been stratified into 3 randomized groups: the first group received 3 injections of movalis into trigger points with the following administration of tablets (15 mg per day); 2nd group received - 3 intramuscular injection movalis with the following administration of tablets (15 mg per day); 3nd - was control. Treatment efficacy has been assessed with the Visual-Analogous scale, a five-point scale for assessment of vertebroneurological symptoms, the Oswestry Disability Index, the McGill Pain Questionnaire, stimulating ENMG. Patients treated with movalis injections into trigger points and intramuscular had no local side-effects. The analgesic effect was more pronounced after three injections into trigger points compared to the intramuscular injection. The efficacy of treatment was the highest in the first group (75,6%) comparing to the 2nd (64,3%) and the 3rd (33,3%) ones.